Overview

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: - Pembrolizumab - Radiation - Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Bevacizumab
Pembrolizumab